Kyfora Bio Launches Kyfecttm - AAV A Next-Generation Transfection Reagent. Engineered For Discovery. Built For Scale.

(MENAFN- PR Newswire)

Delivers 2x increase in AAV titers compared to market alternates.

Reduce plasmid input, halve the bioreactors, and significantly lower cost per dose.

HORSHAM, Pa., Aug. 12, 2025 /PRNewswire/ -- In a groundbreaking step toward advancing gene therapy manufacturing, Kyfora Bio launched KyFectTM - AAV , a next-generation transfection reagent designed specifically for high-yield, scalable viral titers.

As recombinant adeno-associated virus (AAV)-based therapies lead the way in gene therapy innovation, the industry faces persistent challenges related to scalability and cost. With six FDA-approved AAV therapies already on the market and more in late-stage clinical trials, the need to optimize upstream manufacturing has never been greater.

Enter KyFectTM - AAV. Leveraging the long history of Kyfora by Polysciences in specialty chemical manufacturing, KyFectTM - AAV is designed to synergistically enhance plasmid DNA binding and release at the appropriate stages of the transfection process. Built for flexibility and scale, it enables efficient plasmid delivery, high-yield viral titers, and reproducible performance from early-stage discovery through upstream process development.

"KyFectTM – AAV was developed with our customers' entire product lifecycle in mind," said Leena Mol Thuruthippallil, PhD, Vice President of Commercial Strategy and Development at Kyfora Bio. "From early discovery to GMP manufacturing, our reagents empower gene therapy developers to achieve higher titers with fewer resources, accelerating timelines and reducing costs without compromising quality."

With its robust scalability and unmatched flexibility, KyFectTM – AAV stands to transform viral vector manufacturing and to help make life-changing gene therapies more accessible than ever before.

"KyFectTM – AAV represents a significant advancement in upstream AAV manufacturing," said Andrew Ott, CEO at Kyfora Bio. "By delivering consistent, high-yield titers while addressing key scalability and cost-efficiency challenges, we are closer to bringing the promise of gene therapy to those who need it."

About KyFora Bio

Kyfora Bio delivers high-performance transfection reagents, excipients, and next-gen solutions that empower the development of cutting-edge cell and gene therapies. As a subsidiary of Polysciences-an industry leader with over 60 years of chemical manufacturing expertise-Kyfora leverages scientific innovation to revolutionize the future of advanced therapies, from discovery to delivery.

To learn more visit kyforabio or follow us on LinkedIn .

SOURCE Kyfora Bio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN12082025003732001241ID1109918055